Neuroendocrine cancer breast.

One of the major tools to evaluate this type of pathology is the neuroendocrine markers as chromogranin A, serotonin, urinary 5-hydroxy indolacetic acid, and neuron specific enolase.

neuroendocrine cancer breast

They change related to the disease progression, regardless therapy. Some of the drugs that are used for NETs as somatostatin analogs for example octreotide might interfere with glucose metabolism.

Revista Romana de Medicina de Laborator

We analyzed in a retrospective study of 2 years the dynamic of the NET markers and the glycemia profile. Material and Methods.

All the patients had neuroendocrine cancer breast least one assay per year.

  1. Tratament oxiuri copii 1 an
  2. Пальцы у него онемели.

  3. Он был установлен на задней стороне компьютерного кольца и обращен в сторону шифровалки.

  4. Нам нужна ваша помощь.

The dose of octreotide varied from 20 to 50 mg, monthly. The fasting glucose insignificantly changed from baseline after 2 years.

cancer after hodgkins disease ???????? ???? ???????? 2019

No new case of neuroendocrine cancer breast was registered. One case of known diabetes needed insulin but interferon therapy was also added during this time period. The chromogranin A had sustained high values for all the 9 cases, marking the disease progression.

The neuron specific enolase significantly increased, and the serum serotonin as well as the 5HIIA neuroendocrine cancer breast much higher in 2 cases with aggressive carcinoid symptoms. The NET markers and neuroendocrine cancer breast glucose metabolism are most useful tools in the management neuroendocrine cancer breast NETs, yet they are not correlated.

Rezumat Tumorile neuroendocrine NET sunt mult mai frecvente în ultimele decade. Unul din intrumentele majore de evaluare neuroendocrine cancer breast această patologie este reprezentat de dozarea markerilor neuroendocrini precum cromogranina A, serotonina, acidul 5-hidroxi indolacetic urinar şi enolaza neuronal specifică.

Aceştia se schimbă cu progresia tumorală, indiferent de terapie. O parte din medicamentele folosite în NET precum analogii de somatostatin de exemplu, octreotid interferă cu metabolismul glucozei.

Am analizat într-un studiu retrospectiv de-a lungul a 2 ani dinamica markerilor NET şi profilul glicemic. Material si metode. Toţi pacienţii au avut cel puţin o evaluare pe an.

Там проблема с электричеством. - Я не электрик. Позвони в технический отдел. - В куполе нет света.

Doza de octreotid a variat de la 20 la neuroendocrine cancer breast mg lunar. Glicemia s-a modificat nesemnificativ de la bază după 2 ani. Nu s-a înregistrat nici un caz nou de diabet. O pacientă a necesitat insulină pentru diabetul neuroendocrine cancer breast dar între timp s-a adaugat şi terapie cu interferon Cromogranina A a avut valori mari sustinute pentru toate cele 9 cazuri, sugerând progresia bolii.

Enolaza neuronal specifică a crescut semnificativ iar serotonina serică şi 5HIIA au crescut considerabil în 2 cazuri cu simptome severe de sindrom carcinoid. Markerii NET şi metabolismul glucidic sunt instrumente foarte utile in managementul tumorilor neuroendocrine, totusi acestea nu se coreleaza.

Cuvinte cheie: cromogranina A ; tumora neuroendocrina ; serotonina References 1. Neuroendocrine tumors. Endocr Relat Cancer. DOI: Oberndorfer S. Karzinoide tumoren des dunndarms.

Frank Z Pathol. Google Scholar 3.

Most Downloaded Articles

Carcinoid Tumors. Bellizzi AM.

paraziti u stolici kod pasa

Assigning site of origin in metastatic neuroendocrine neoplasms: a clinically significant application of diagnosis immunohistochemistry. Adv Anat Pathol. Chromogranins A, B, C: widespread consitituents of secretory vesicles.

Ann N Y Neuroendocrine cancer breast Sci.

Chromogranin A, neuron specific enolase, carcinoembryonic antigen, and hydroxyindole acetic acid evaluation in patients with neuroendocrine tumors. Regul Pept. The poor prognosis factors in G2 neuroendocrine tumor. Rom J Morphol Embryol.

1. Introduction

Google Scholar The dedifferentiation of neuroendocrine tumor metastases: myth or reality? PubMed Google Scholar Octreotide for the treatment of hypoglycemia after insulin glargine overdose.

J Emerg Med. Biochemical testing for neuroendocrine tumors. The clinical relevance of chromogranin A as a biomarker for gastroenteropancreatic neuroendocrine tumors. Endocrinol Metab Clin North Am ;40 1 Well-differentiated neuroendocrine tumor and osteoporosis: incidental finding? Treatment of malignant midgut carcinoid tumours with a long-acting somatostatin analogue octreotide.

Accepted Apr Copyright © The Authors. This is an open access article under the terms of the Creative Commons Attribution License, which permits use, distribution and reproduction in any medium, provided the original work is properly cited.

Acta Oncol. Long-term clinical outcome of somatostatin analogues for treatment of pregressive, metastatic, well-differentiated entero-pancreatic endocrine carcinoma. Ann Oncol. Predictive factors of efficacy of the somatostatin analogue octreotide as first line therapy for advanced pancreatic endocrine carcinoma.